SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for CAMTEK LTD (CAMT) (CIK 0001109138) (CAMT) — Apr 17, 2020

CAMTEK LTD (CAMT) (CIK 0001109138)
Date: April 17, 2020 · CIK: 0001109138 · Accession: 0000000000-20-003334

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237680

Date
April 16, 2020
Author
Moshe Eisenberg
Form
UPLOAD
Company
CAMTEK LTD (CAMT) (CIK 0001109138)

Letter

April 16, 2020 Moshe Eisenberg Chief Financial Officer Camtek Ltd. Ramat Gavriel Industrial Zone, P.O. Box 544, Migdal Ha’Emek Israel Re:Camtek Ltd. Registration Statement on Form F-3 Filed April 14, 2020 File No. 333-237680 Dear Mr. Eisenberg: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard H. Gilden, Esq.

Show Raw Text
April 16, 2020
Moshe Eisenberg
Chief Financial Officer
Camtek Ltd.
Ramat Gavriel Industrial Zone,
P.O. Box 544,
Migdal Ha’Emek Israel
Re:Camtek Ltd.
Registration Statement on Form F-3
Filed April 14, 2020
File No. 333-237680
Dear Mr. Eisenberg:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Richard H. Gilden, Esq.